How it works:
Metformin belongs to the biguanide class and is considered first-line therapy for type 2 diabetes. It reduces hepatic glucose production, enhances peripheral insulin sensitivity, and increases glucose uptake in muscle tissue. It does not stimulate insulin secretion, which minimizes the risk of hypoglycemia during monotherapy.
The sustained-release (SR) formulation ensures gradual release of the active ingredient, providing more stable blood glucose control and improved gastrointestinal tolerability.
Recommended for:
Clinical evidence:
Metformin is one of the most extensively studied medications in endocrinology. Large international trials, including the UKPDS study, demonstrated reduced risk of vascular complications in patients with type 2 diabetes.
Clinical data confirm its effectiveness in lowering HbA1c and improving long-term outcomes.
Extended-release formulations have shown improved gastrointestinal tolerability compared to immediate-release metformin.
Type 2 diabetes mellitus, particularly in overweight patients. Used to control blood glucose levels, reduce insulin resistance, and help prevent diabetic complications. It may be used alone or in combination with insulin or other antidiabetic agents.
The medication should be taken orally with or after meals and swallowed whole with water. Extended-release tablets must not be crushed or chewed. Dosage and duration of therapy are determined individually by a healthcare provider.
Contraindications:
Side effects:
